Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary care patient interests in joining a planned multi-cancer early detection clinical trial.

Cancer medicine·2024
Same author

COVID-19 mRNA Vaccination Trends Among Immunocompromised Patients.

Journal of the American Board of Family Medicine : JABFM·2024
Same author

Primary Care Provider Receptivity to Multi-Cancer Early Detection Test Use in Cancer Screening.

Journal of personalized medicine·2023
Same author

Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening.

Journal of personalized medicine·2023
Same author

Barbershop-Facilitated Community-to-Clinic Linkage Implementation Program: Rationale and Protocol for a Novel Program to Prevent Hypertension Among Black Men.

American journal of hypertension·2023
Same author

Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.

JCO oncology practice·2023

Related Experiment Video

Updated: May 10, 2026

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

23.9K

Multi-cancer early detection tests: Attributes for clinical implementation.

Jon O Ebbert1, Ernest T Hawk2, Christopher V Chambers3

  • 1Mayo Clinic, Rochester, MN, USA.

Cancer Biomarkers : Section a of Disease Markers
|April 2, 2025
PubMed
Summary
This summary is machine-generated.

Blood-based multi-cancer early detection (MCED) tests offer a promising approach to complement existing single-cancer screening. These tests aim to improve cancer detection rates and patient outcomes by identifying multiple cancers early.

Keywords:
accuracyadherenceclinical implementationeffectivenessmulti-cancer early detection

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

7.8K
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.4K

Related Experiment Videos

Last Updated: May 10, 2026

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

23.9K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

7.8K
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.4K

Area of Science:

  • Oncology
  • Biotechnology
  • Medical Diagnostics

Background:

  • Current cancer screening guidelines cover limited cancer types, missing over half of new U.S. cases annually.
  • Existing single-cancer screening methods show variability in accuracy, adherence, and effectiveness.
  • Advances in technology enable blood-based multi-cancer early detection (MCED) tests.

Purpose of the Study:

  • To address the unmet need in cancer screening by developing blood-based MCED tests.
  • To complement standard of care (SoC) screening and improve early cancer detection.
  • To identify core attributes of MCED testing requiring clinical data for widespread adoption.

Main Methods:

  • Leveraging high-throughput technologies and machine learning for MCED test development.
  • Focusing on test performance metrics such as sensitivity, specificity, PPV, and NPV.
  • Proposing core attributes for which clinical data are essential.

Main Results:

  • MCED tests show potential for early detection of multiple cancers from a single blood draw.
  • These tests can complement SoC screening, improving adherence and accessibility.
  • Published data primarily focus on test performance, with clinical utility studies pending.

Conclusions:

  • MCED tests hold significant promise for improving cancer outcomes by enabling earlier detection.
  • Further clinical data are needed to demonstrate utility and establish optimal implementation strategies.
  • MCED tests require FDA pre-market approval and robust evidence for widespread clinical practice integration.